Please login to the form below

Not currently logged in


This page shows the latest tremelimumab, news and features for those working in and with pharma, biotech and healthcare.

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

CASPIAN also included an arm that received Imfinzi, chemo and AZ’s experimental CTLA4 inhibitor tremelimumab, but that data has yet to mature and is expected to be ready next year. ... So far, adding tremelimumab to Imfinzi hasn’t been able to

Latest news

More from news
Approximately 5 fully matching, plus 48 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...